01.02.2024 | Tracker
Top 50 Pharma Tracker: eHCPs share pharma sponsored webinar, nurse guidelines and recent approvals
By Aman Jandu Discover what healthcare professionals (eHCPs) think about pharmaceutical products and their manufacturers, as it happens, through CREATION.co’s tracking updates. How are eHCPs responding to drug launch news? How are eHCPs talking about or engaging with the Top 50 pharma companies on social media? Each week, CREATION.co’s tracking updates bring you the latest insights from the conversation of eHCPs across the globe discussing these topics and more.
The Top 50 Pharmaceutical Companies mentioned by eHCPs on X
| January Rank | December Rank | Company Name | Total Mentions | Account Mentions | Account Retweets |
|---|---|---|---|---|---|
| 1 | 1 | Pfizer | 3,458 | 271 | 0 |
| 2 | 2 | Moderna | 1,942 | 129 | 0 |
| 3 | 3 | Johnson & Johnson | 545 | 172 | 1 |
| 4 | 5 | AstraZeneca | 418 | 166 | 5 |
| 5 | 4 | GSK | 366 | 88 | 9 |
| 6 | 6 | Novavax | 294 | 22 | 0 |
| 7 | 11 | Bayer | 281 | 94 | 3 |
| 8 | 7 | BioNTech | 230 | 8 | 0 |
| 9 | 16 | Lilly | 214 | 99 | 0 |
| 10 | 12 | Roche | 212 | 72 | 6 |
| 11 | 13 | Novo Nordisk | 210 | 114 | 4 |
| 12 | 8 | Merck & Co | 179 | 113 | 6 |
| 13 | 10 | Sanofi | 174 | 81 | 12 |
| 14 | 15 | Novartis | 169 | 94 | 2 |
| 14 | 20 | AbbVie | 169 | 150 | 2 |
| 16 | 42 | Grifols | 164 | 2 | 0 |
| 17 | 21 | Abbott | 151 | 147 | 3 |
| 18 | 9 | Gilead Sciences | 129 | 53 | 1 |
| 19 | 29 | Takeda | 114 | 104 | 0 |
| 20 | 25 | Organon | 61 | 0 | 0 |
| 21 | 24 | Servier | 59 | 8 | 5 |
| 22 | 17 | BMS | 58 | 50 | 0 |
| 23 | 23 | Boehringer Ingelheim | 48 | 40 | 2 |
| 24 | 19 | Vertex | 44 | 44 | 4 |
| 25 | 27 | Regeneron | 43 | 20 | 0 |
| 25 | 18 | Amgen | 39 | 19 | 2 |
| 27 | 33 | Biogen | 36 | 15 | 0 |
| 28 | 22 | Otsuka | 32 | 1 | 0 |
| 28 | 25 | Fresenius | 32 | 26 | 0 |
| 30 | 37 | Eisai | 20 | 7 | 1 |
| 31 | 14 | Astellas | 19 | 13 | 0 |
| 31 | 27 | Daiichi Sankyo | 19 | 14 | 6 |
| 33 | 39 | Viatris | 15 | 1 | 0 |
| 34 | 31 | Merck KGaA | 13 | 7 | 3 |
| 35 | 39 | UCB | 12 | 12 | 5 |
| 36 | 32 | Ipsen | 8 | 7 | 0 |
| 37 | 30 | Menarini | 7 | 1 | 0 |
| 37 | 33 | Bausch | 7 | 3 | 1 |
| 39 | 43 | Teva | 6 | 6 | 4 |
| 40 | 36 | Sun | 5 | 2 | 0 |
| 40 | 37 | CSL | 5 | 3 | 0 |
| 42 | 50 | Incyte | 4 | 3 | 0 |
| 43 | 35 | Jazz Pharmaceuticals | 3 | 0 | 0 |
| 44 | 41 | Chugai | 2 | 1 | 1 |
| 45 | 50 | Horizon | 1 | 1 | 0 |
| 50 | 44 | CSPC | 0 | 0 | 0 |
| 50 | 44 | Shanghai | 0 | 0 | 0 |
| 50 | 50 | Perrigo | 0 | 0 | 0 |
| 50 | 50 | Sino | 0 | 0 | 0 |
| 50 | 50 | Jiangsu Hengrui | 0 | 0 | 0 |
The latest insights from eHCPs mentioning the Top 50 Pharmaceutical Companies
The five pharmaceutical companies that were mentioned the most by eHCPs on X in January 2024 were Pfizer, Moderna, Johnson & Johnson, GSK and AstraZeneca.
CREATION.co identified 8,494 eHCP mentions of pharmaceutical companies in January 2024, decreasing by 18% over the previous month.
On 16 January, cardiologist Pradeep Natarajan celebrated Vertex Pharmaceuticals’ “big news” for receiving FDA expanded-approval of Casgevy. The CRISPR-based therapy received approval for treating transfusion-dependent beta thalassaemia.
Big news! @VertexPharma @CRISPRTX ex vivo CRISPR-based therapy (Casgevy) for sickle cell disease expanded to transfusion-dependent beta thalassemia.
"In a clinical trial, 89% of beta thalassemia patients who received a one-time infusion of Casgevy no longer required blood… https://t.co/wx192WzXfK
— Pradeep Natarajan (@pnatarajanmd) January 16, 2024
On the same day in Hong Kong, oncologist Erika Hamilton shared a post from her “fantastic time” spent with AstraZeneca and Daiichi Sankyo discussing treatments and therapies for HER2low breast cancer.
Fantastic time in #hongkong discussing treatment patterns and novel therapies for #HER2low.
Thank you to @Oncology_at_AZ @EUdaiichisankyo. pic.twitter.com/t9lNzIl8rL
— Erika Hamilton, MD (@ErikaHamilton9) January 16, 2024
And on 29 January, eHCPs shared a link to register for a webinar for empowering women surgeons. The webinar was developed in collaboration with Johnson & Johnson MedTech, with the goal of considering the challenges, dynamics and advantages faced. The webinar registration link was shared by 13 eHCPs.
⏰ Tomorrow: 'Empowering Women Surgeons' webinar. Your chance to interact and learn at 8am EST. @mumbaCK @nganttmd @kpmcguiremd @dmcsurg @dmcsurg @traumapty @aprilroslani @SWexner @AmCollSurgeons @WomenSurgeons @JNJMedTech 🌐https://t.co/yA27OBBgf7 #IamAIS #some4surgery #DEI pic.twitter.com/N3YhX93uPr
— AIS Channel (@AISChannel) January 28, 2024
The top shared links by eHCPs when mentioning a Top 50 pharma company discussed:
- A handbook for nurses and HCPs for administration of IV medication.
- A webinar for “Empowering Women Surgeons”, in collaboration with Johnson & Johnson Innovative Medicine.
- An article discussing Novavax’s COVID-19 vaccine protection.
CREATION.co continues to analyse online eHCP conversation on a variety of topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights.
To stay up to date, you can sign up to CREATION.co’s monthly eJournal.
Methodology notes:
-
- In January 2024, CREATION Pinpoint® identified 8,494 healthcare professional authored posts on X (Twitter) from 3,405 individual eHCPs mentioning a Top 50 Pharmaceutical company (according to revenue).
- Data for this research was analysed from the online X conversations of eHCPs in all languages mentioning a Top 50 Pharmaceutical company between 01 – 31 January 2024.
- Unless otherwise specified, mentions of a company are not limited to its X account(s).
- In some cases, an X post may mention more than one company account (e.g. @abbottnews and @abbottglobal) – this only counts as one Company Mention and Account Mention.
- Johnson & Johnson was included as a whole, encompassing its pharmaceutical subsidiary, Johnson & Johnson Innovative Medicine (previously Janssen). In January 2024, 41 of these posts mentioned Johnson & Johnson Innovative Medicine or Janssen.
